IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1 + and BCR::ABL1 ‐like B‐acute lymphoblastic leukaemia
British Journal of Haematology · 2024-01 · 204 (1) · 229-239
DOI: 10.1111/bjh.19142 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 23.10.2023. Verfasst von Catherine K Gestrich und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Hospitals Cleveland Medical Center, University Hospitals Rainbow Babies and Children's Hospital and Case Western …. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Therapeutic management and prognostication for patients with B‐acute lymphoblastic leukaemia (B‐ALL) require appropriate disease subclassification. BCR::ABL1 ‐like B‐ALL is unique in that it is defined by a gene expression profile similar to BCR::ABL1 + B‐ALL rather than a unifying recurrent translocation. Current molecular/cytogenetic techniques to identify this subtype are expensive, not widely accessible, have long turnaround times and/or require an adequate liquid biopsy. We have studied a total of 118 B‐ALL cases from three institutions in two laboratories to identify surrogates for BCR::ABL1 +/like B‐ALL. We report that immunoglobulin joining chain (IGJ) and spermatogenesis associated serine‐rich 2‐like (SPATS2L) immunohistochemistry (IHC) sensitively and specifically identify BCR::ABL1 +/like B‐ALL. IGJ IHC positivity has a sensitivity of 83%, a specificity of 95%, a positive predictive value (PPV) of 89% and a negative predictive value (NPV) of 90%. SPATS2L staining has similar sensitivity and NPV but lower specificity (85%) and PPV (70%). The presence of either IGJ or SPATS2L staining augments the sensitivity (93%) and NPV (95%). While these findings would need to be validated in larger studies, they suggest that IGJ and/or SPATS2L IHC may be utilized in identifying BCR::ABL1 ‐like B‐ALL or in selecting B‐ALL cases for confirmatory molecular/genetic testing, particularly in resource‐limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University Hospitals Cleveland Medical Center, University Hospitals Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio, USA.
- Division of Hematology and Oncology, Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
- Department of Pathology, Boston Children Hospital, Boston, Massachusetts, USA.
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Kwadwo A Oduro
Zitieren
APA
Gestrich, C. K., De Lancy, S. J., Kresak, A., Meyerson, H., Pateva, I., Yalley, A. K., Ryder, C., Shetty, S., Bledsoe, J., Moore, E. M., & Oduro, K. A. (2024). IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1 + and BCR::ABL1 ‐like B‐acute lymphoblastic leukaemia. British Journal of Haematology, 204(1), 229-239. https://doi.org/10.1111/bjh.19142
Vancouver
Gestrich CK, De Lancy SJ, Kresak A, Meyerson H, Pateva I, Yalley AK, et al. IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1 + and BCR::ABL1 ‐like B‐acute lymphoblastic leukaemia. British Journal of Haematology. 2024;204(1):229-239. doi:10.1111/bjh.19142
BibTeX
@article{Gestrich2024,
author = {Gestrich, Catherine K and De Lancy, Shanelle J and Kresak, Adam and Meyerson, Howard and Pateva, Irina and Yalley, Akua K and Ryder, Christopher and Shetty, Shashirekha and Bledsoe, Jacob and Moore, Erika M and Oduro, Kwadwo A},
title = {IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1 + and BCR::ABL1 ‐like B‐acute lymphoblastic leukaemia},
journal = {British Journal of Haematology},
year = {2024},
volume = {204},
number = {1},
pages = {229--239},
doi = {10.1111/bjh.19142}
}
EUVIMED